Search results
Results from the WOW.Com Content Network
Purified duck embryo vaccine (PDEV) was the first vaccine developed for human use in treating pre- and postexposure to the rabies virus. It was developed in 1957 and was made of dried, killed rabies virus. Vaccination with PDEV involved a series of intradermal injections over several days.
The Institute’s NIH-funded HIV-1 research program leads a consortium of several HIV investigators nationwide who develop and test combinations of novel immunotherapies in clinical trials. [4] Wistar’s vaccine and immune research has resulted in the development of several significant vaccines:
The rabies vaccine is a vaccine used to prevent rabies. [11] There are several rabies vaccines available that are both safe and effective. [ 11 ] Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. [ 12 ]
The number of recorded human deaths from rabies in the United States has dropped from 100 or more annually in the early 20th century to one or two per year because of widespread vaccination of domestic dogs and cats and the development of human vaccines and immunoglobulin treatments.
The successor to PDVI, the Dengue Vaccine Initiative was an IVI-led consortium with the World Health Organization, the Sabin Vaccine Institute, the Initiative for Vaccine Research (IVR), and the International Vaccine Access Center (IVAC) at Johns Hopkins University. DVI continued the work of PDVI and focused on laying the groundwork for dengue ...
It is noted for developing veterinary and human vaccines for foot-and-mouth disease, rabies, bacterial vaccines, canine vaccines, hepatitis, measles, MMR and DPT. IIL is a major supplier of DPT, TT and hepatitis B vaccines to India's large Universal Immunization Programme. [5] [6] IIL has three vaccine manufacturing facilities in India. The ...
During his time at Wistar, Plotkin worked on several vaccines; chief among them are vaccines for rubella, rabies, rotavirus, and cytomegalovirus (CMV). He developed a vaccine for rubella, based upon the RA 27/3 strain of the virus (also developed by Plotkin using WI-38, a fetal-derived human cell line), which was released to the public in 1969. [8]
This approach aims to develop vaccines that are both more cost-effective and have better protective coverage, addressing the ongoing global need for rabies prevention. [46] Interestingly, the rabies virus vaccine that was created using the SAD-B19 complex, which includes the L-P protein, was utilized in the creation of a vaccine for SARS-CoV-2.